<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20261004071287N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-19</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effects of adding Graston and dry needling to exercise therapy on painful points of the upper trapezius muscle</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of adding Graston Technique versus Dry Needling to Therapeutic Exercise on Upper Trapezius Trigger Point Pain in Individuals with Upper Crossed Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/94076</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants will be randomly assigned to one of two study groups using block randomization with a block size of four and an allocation ratio of 1:1. Group A will receive dry needling, while Group B will receive myofascial release using the Graston Technique Allocation will be implemented using sealed envelopes.Block randomization is a method of randomly allocating participants to study arms to maintain balance in the number of participants assigned to each group throughout the recruitment period. In this method, the allocation sequence is divided into a series of blocks,with the number of allocations to each group predetermined and equal within each block, consistent with the intended allocation  ratio. However, the order of assignments within each block is determined randomly.This method is particularly useful in studies with small to moderate sample sizes or when premature termination of recruitment is possible. Compared with simple randomization, block randomization reduces numerical imbalances between study groups during recruitment and facilitates a more balanced comparison between the study arms, Blinding description: Due to the nature of the interventions, blinding of participants and the treating therapist will not be feasible, as dry needling and the Graston Technique are distinguishable by both the participants and the therapist during treatment. However, to minimize the risk of outcome assessment bias, the outcome assessor will be blinded to group allocation.
Outcome assessments will be performed at baseline and at the end of the sixth week by an assessor who will not be involved in random sequence generation, group allocation, or intervention delivery. The assessor will not be informed of the type of intervention received by each participant. Assessments will be conducted at a time and location separate from the treatment sessions. Participants will also be instructed not to disclose their assigned intervention to the outcome assessor during the assessments.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Upper Trapezius Trigger Point Pain in Individuals with Upper Crossed Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: First Intervention group: ‏Using the Graystone tool in addition to the exercise therapy program twice a week for up to 6 weeks. Intervention 2: Second Intervention group: ‏Dry needling with acupuncture needles (size 0.25 × 25 mm) applied to trigger points, in addition to the exercise program, twice a week for up to 6 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The present study has been registered as a proposal for a sports medicine residency thesis. The thesis resulting from this proposal, including participant data (all data), the study protocol, statistical analysis, and the study report (including all variables), will be made available to Tehran University of Medical Sciences and the Department of Sports Medicine. It should be noted that access to raw data not published in the final report or article requires contacting the responsible researcher of the study.

When:
The present study will begin on 1405/8/1 (October 23, 2026) and is projected to take one year for all stages until submission as a thesis. Access to raw data not published in the final report or article will be possible after publication of the article through contact with the responsible researcher of the study.

To whom:
The data obtained from this research will be made available to all requesting individuals, and there will be no restrictions.

Conditions:
There are no restrictions on the use, publication, or processing of the data from this study, provided that the necessary coordination has been made with the responsible researcher of the study and the required permission has been issued by the responsible researcher.

Where to obtain:
To access the information of this study, the applicant can contact the responsible researcher of this study via email or telephone.

How to obtain:
The permission to use the information will be issued to the applicant as soon as possible after receiving and reviewing the email or establishing telephone contact, and then the requested information will be sent to the applicant immediately via their email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mojdeh Yousefi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>End of Keshavarz Boulevard, Dr. Gharib Street, Imam Khomeini Hospital Complex, Mehdi Clinic, First Floor, Sports Medicine Department</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 21 6119 0000</telephone>
        <email>mojde.yousefi2018@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Abolhasani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Street, before Hasanabad Square, Sina Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>mojde.yousefi2018@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients presenting with Upper Crossed Syndrome (UCS) on clinical postural assessment, reporting pain in the upper trapezius region, and exhibiting a trigger point in the upper trapezius muscle upon palpation using the pad of the index finger
Willingness to participate in the study and provision of informed consent
Age between 18 and 55 years
Participants of either sex (male or female)
Absence of orthopedic disorders or diseases that would prevent participation in the exercise program
A baseline Numeric Rating Scale (NRS) pain score of 3–7 at the initial visit
No participation in a regular exercise program and no receipt of pain-relieving treatments, such as physiotherapy, during the preceding 4 weeks
No history of fractures involving the cervical or shoulder regions
No history of surgery involving the cervical or shoulder regions
No history of trauma to the cervical or shoulder regions and no history of whiplash injury within the preceding 6 weeks
No diagnosis of fibromyalgia
Absence of cervical radicular pain, cervical myelopathy, musculoskeletal pain attributable to conditions other than UpperCrossed Syndrome (UCS), or pain resulting from cervical spinal canal stenosis
No history of migraine, tension-type headache, or central nervous system disorders, such as MS
No diagnosis of rheumatoid arthritis, neoplastic lesions, osteoporosis, thyroid disorders, or diabetes mellitus
No history of long-term corticosteroid use
No open wounds in the upper trapezius region
Absence of psychological or cognitive disorders that would interfere with performing the exercises or participating in the study
Absence of contraindications to carotid artery massage, such as a history of myocardial infarction, stroke within the preceding three months, transient ischemic attack (TIA), or ventricular arrhythmia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M63</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disorders of muscle in diseases classified elsewhere</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First Intervention group: ‏Using the Graystone tool in addition to the exercise therapy program twice a week for up to 6 weeks</i_keyword>
      <i_keyword>Second Intervention group: ‏Dry needling with acupuncture needles (size 0.25 × 25 mm) applied to trigger points, in addition to the exercise program, twice a week for up to 6 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Numeric Pain Rating Scale. Timepoint: Before the start of the intervention and 6 weeks after the end of the intervention. Method of measurement: The patient is given a sheet on which a ruler with numbers from 0 to 10 is printed. The patient must circle the number that indicates the intensity of their pain.</prim_outcome>
      <prim_outcome>Neck Disability Index (NDI). Timepoint: Before the start of the intervention and 6 weeks after the end of the intervention. Method of measurement: Patient-completed, condition-specific functional status questionnaire.</prim_outcome>
      <prim_outcome>CranioVertebral Angle. Timepoint: Before the start of the intervention and 6 weeks after the end of the intervention. Method of measurement: Using photography from the lateral view of the patient's neck and Kinova software.</prim_outcome>
      <prim_outcome>Pressure pain threshold (PPT). Timepoint: Before the start of the intervention and 6 weeks after the end of the intervention. Method of measurement: Pressure algometers.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Deputy of Research and Technology, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-29</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>End of Keshavarz Boulevard, Imam Khomeini Hospital Complex, Mahdi Clinic Building, First Floor, Sports Medicine Department Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
